Evaluating the impact of possible interobserver variability in CBCT-based soft-tissue matching using TCP/NTCP models for prostate cancer radiotherapy

Xiangbin Zhang, Xin Wang, Xiaoyu Li, Li Zhou, Shihong Nie, Changhu Li, Xuetao Wang, Guyu Dai, Zhonghua Deng and Renming Zhong*

Abstract

Background: Prostate alignment is subject to interobserver variability in cone-beam CT (CBCT)-based soft-tissue matching. This study aims to analyze the impact of possible interobserver variability in CBCT-based soft-tissue matching for prostate cancer radiotherapy.

Methods: Retrospective data, consisting of 156 CBCT images from twelve prostate cancer patients with elective nodal irradiation were analyzed in this study. To simulate possible interobserver variability, couch shifts of 2 mm relative to the resulting patient position of prostate alignment were assumed as potential patient positions (27 possibilities). For each CBCT, the doses of the potential patient positions were re-calculated using deformable image registration-based synthetic CT. The impact of the simulated interobserver variability was evaluated using tumor control probabilities (TCPs) and normal tissue complication probabilities (NTCPs).

Results: No significant differences in TCPs were found between prostate alignment and potential patient positions (0.944 ± 0.003 vs 0.945 ± 0.003, P = 0.117). The average NTCPs of the rectum ranged from 5.16 to 7.29 (%) among the potential patient positions and were highly influenced by the couch shift in the anterior–posterior direction. In contrast, the average NTCPs of the bladder ranged from 0.75 to 1.12 (%) among the potential patient positions and were relatively negligible.

Conclusions: The NTCPs of the rectum, rather than the TCPs of the target, were highly influenced by the interobserver variability in CBCT-based soft-tissue matching. This study provides a theoretical explanation for daily CBCT-based image guidance and the prostate-rectum interface matching procedure.

Trial registration: Not applicable.

Keywords: Prostate cancer, Image-guided radiotherapy, Cone-beam CT, Interobserver variability, Tumor control probabilities, Normal tissue complication probabilities

Background

As suggested by the National Comprehensive Cancer Network (NCCN) guidelines [1], the accuracy of prostate cancer radiotherapy should be verified by daily prostate alignment. The European Society for Radiotherapy and Oncology (ESTRO) guidelines recommended that...
prostate alignment must be based on either fiducial markers or CT-based soft-tissue matching [2]. Among these approaches, cone-beam CT (CBCT) is the most prevalent image guidance technique. However, CBCT-based soft-tissue matching is subject to interobserver variability, which is an obstacle in the standardization of prostate cancer image-guided radiotherapy (IGRT).

Several studies [3–8] have confirmed the interobserver variability in CBCT-based soft-tissue matching for prostate cancer radiotherapy. However, these previous studies primarily focused on analyzing the induced factors (e.g., observers’ experience and image quality). To date, far too little attention has been given to the impact of interobserver variability in CBCT-based soft-tissue matching.

The purpose of this paper is to analyze the impact on interobserver variability in CBCT-based soft-tissue matching, thereby providing a theoretical explanation for the standardization of prostate cancer IGRT. To simulate possible interobserver variability, couch shifts of 2 mm relative to the resulting patient position of prostate alignment were assumed as potential patient positions. The dosimetric impact of the simulated interobserver variability on targets and organs as risk (OARs) was then evaluated using tumor control probabilities (TCPs) and normal tissue complication probabilities (NTCPs).

Methods
Patient data acquisition
In this study, retrospective data, consisting of 156 CBCT images from twelve prostate cancer patients with elective nodal irradiation were analyzed. All patients were initially planned using volumetric-modulated arc therapy (VMAT) with prescription doses of 76 Gy for the prostate gland and seminal vesicles (CTV1) and 60.8 Gy for the pelvic lymph nodes (CTV2) in 38 daily fractions, and were replanned with a prescription dose of 16 Gy for the prostate gland only in 8 daily fractions. To enable a homogenous analysis, the patients were analyzed using the initial plans. The clinical target volume (CTV) to planned target volume (PTV) margin is 5 mm in all directions. Notably, because the anatomical changes were similar between two consecutive fractions, the CBCT images were analyzed for every three fractions.

According to our clinical setting, the slice thickness of planning CT (SOMATOM Definition AS+, Siemens Medical Solutions, Forchheim, Germany) was 3 mm. Full-arc CBCT (On-board imaging v1.4, Varian Medical Systems, Palo Alto, CA, USA) was acquired on an Edge treatment system (Varian Medical Systems, Palo Alto, CA, USA) with a slice thickness of 2 mm. The patients were required to empty their rectum and bladder, drink 500 ml of water and provide feedback on the bladder filling state prior to CT localization and treatment delivery.

Dose reconstruction
Synthetic CT, generated by planning CT to CBCT deformable image registration in Velocity (v3.2.1, Varian Medical Systems, Palo Alto, CA), was used for interfractional dose calculation. Then, the CTV1, CTV2, rectum (whole organ), and bladder were manually delineated on CBCT and mapped to synthetic CT. Finally, the origin plan is applied to the synthetic CT to calculate the interfractional dose in the Eclipse planning system (v13.6, Varian Medical Systems, Palo Alto, CA). Because the delineation of small bowel is subject to severe streaking artifact of CBCT images, the impact of interobserver variability on the small bowel was not included in this study. To avoid interobserver variability in delineations, the targets and OARs on planning CT and CBCT were contoured by the same radiation oncologist.

Possible interobserver variability simulation
Prostate alignment visually aligns the prostate on planning CT and CBCT. In this study, prostate alignment was performed and recorded in the Mosaic system by an experienced radiation therapist. To simulate possible interobserver variability, combinations of 0- and 2-mm couch shifts in left–right (LR), superior-inferior (SI), and anterior–posterior (AP) directions relative to the resulting patient position of prostate alignment were assumed as potential patient positions. Consequently, a total of 27 potential patient positions were determined for each CBCT. Notably, we re-calculated the dose using the origin plan for every couch shift. The couch shifts relative to the resulting patient position of prostate alignment are listed in Table 1.

TCPs and NTCPs
The TCPs and NTCPs were calculated using the linear-quadratic Poisson model and the Lyman-Kutcher-Burman model, respectively. These calculations were performed using the open-sourced pyradiobiology package [9] and the physical dose exported from the Eclipse planning system. The radiobiology parameters and endpoints used for TCP/NTCP calculations were specified in previous studies [10–12] and listed in Table 2.

Data analysis
The volumes of the rectum and bladder were calculated in the Eclipse planning system. The impact of the simulated interobserver variability on the targets was evaluated using TCPs and the $V_{95}$, $D_{98}$, $D_{2}$, and mean doses of CTV1 and CTV2. The impact of the simulated interobserver variability on the OARs was evaluated using NTCPs and the $V_{50}$, $V_{60}$, and $V_{70}$ of the rectum and bladder. Moreover, an independent sample t-test
was performed to compare the resulting TCPs, one-way analysis of variance (ANOVA) was performed to compare the resulting NTCPs using the open-sourced statsmodels packages [13], and \( P < 0.05 \) was regarded as statistically significant.

### Results

#### The CTV volume changes and the rectal and bladder filling state

As shown in Table 3, the volumes of CTV1 and CTV2 were 56.63±33.09 and 398.95±118.91 (cc), respectively. The average volume changes of CTV1 ranged from −12.80 to 6.80 (%), and those of CTV2 ranged from −3.20 to 2.58 (%). The absolute and relative volume variations of the rectum and bladder were −4.9±13.3/9.0±61.0 (cc) and −6.1±14.0/15.7±31.4 (%), respectively (Additional file 1). These results indicate that the patients complied with the rectal emptying and bladder filling protocol.

#### The impact of the simulated interobserver variability on targets

Compared to the resulting dose parameters of prostate alignment, the absolute deviations of the \( V_{95} \), \( D_{98} \), \( D_{2} \), and mean dose in CTV1 were 0.18±0.37 (%), 0.82±1.13 (%), 0.54±0.54 (%), and 0.16±0.13 (%), and those in CTV2 were 0.28±0.52 (%), 0.67±0.99 (%), 0.63±0.66 (%), and 0.14±0.22 (%) of the prescription doses for the 4212 potential patient positions of the 156 CBCT images, as shown in Fig. 1.

Figure 2 shows that no significant differences in TCPs were found between prostate alignment and the potential patient positions, which means that the simulated interobserver variability has a minor impact on the CTV1.

#### The impact of the simulated interobserver variability on OARs

As shown in Fig. 3, the volumetric dose parameters and NTCPs of the rectum were highly influenced by couch shifts in the anterior–posterior (AP) direction. On
average, a 2-mm couch shift in the posterior direction will contribute to 2.88 (%), 4.18 (%), 4.84 (%), and 0.97 (%) decrease in the $V_{95}$, $V_{60}$, $V_{50}$, and NTCPs of the rectum, respectively. The results of ANOVA indicate that the simulated interobserver variability has a statistical impact on the NTCPs of the rectum ($P < 0.001$).

In contrast, the volumetric dose parameters of the bladder were highly influenced by both the couch shifts in the AP and superior-inferior (SI) directions, as shown in Fig. 4. However, the average NTCPs of the bladder were within 1.12 (%) and relatively low. To an extent, the impact of the simulated interobserver variability on the NTCPs of the bladder is negligible.

Figure 5 shows an example of interobserver variability impact on dose volumetric histogram. In this treatment fraction, the decrease in the NTCP of the rectum was 1.16 (%), while the increase in the NTCP of the bladder was only 0.19 (%), using a 2-mm couch shift in the posterior direction.

**Discussion**

For the standardization of prostate cancer IGRT, it is valuable to train observers to eliminate the interobserver variability in CBCT-based soft-tissue matching. Therefore, in this study, we attempted to analyze the impact of possible interobserver variability on targets and critical OARs, thereby providing a theoretical explanation for the clinical practice of CBCT-based soft-tissue matching. Our analysis shows that only the NTCPs of the rectum were highly influenced by the simulated interobserver variability.
The TCPs of CTV1 were insensitive to simulated interobserver variability, which suggests the robustness of CBCT-based soft-tissue matching in terms of target localization. Surprisingly, this result is consistent with previous clinical trials. Napieralska et al. [14] reported that no significant differences in five-year progression-free survival were found between fiducial- and bone-based IGRT. As reported by Kotecha et al. [15] and Li et al. [16], CBCT-based soft-tissue matching is superior to fiducial-based IGRT in terms of target dosimetry, but a favorable rate of biochemical control was achievable using both IGRT techniques. This implies that a more accurate prostate target localization IGRT technique was not correlated with superior TCP.

Theoretically, various studies have demonstrated that a 3-mm PTV margin is sufficient [17, 18]. Therefore, the CTV1 dosimetry would not be deteriorated by the 2-mm interobserver variability simulation because a 5-mm PTV margin was used in this study. Furthermore, several studies [19–21] have confirmed that PTV dosimetry is not sensitive to anatomical changes. Under this condition, the factors affecting the CTV1 dosimetry are interfractional deformation and intrafractional motion. Mayyas et al. [22] reported that
prostate interfractional deformations were mainly due to rectal volume variation. Hence, the rectal emptying protocol was strictly carried out in our hospital. As a result, the absolute volume variations of the rectum were $-4.9 \pm 13.3$ ml, negligibly small. In addition, Shelton et al. [23] verified that the intrafractional prostate motion was almost within 1 mm for the use of VMAT. This implies that a 5-mm PTV margin is sufficient to compensate for interfractional deformation, intrafractional motion, and simulated interobserver variability.

For CTV2, the ESTRO guidelines [2] recommended a 7-mm PTV margin, while a 5-mm PTV margin was used in this study. However, the changes in the CTV2 dosimetry induced by the simulated interobserver variability were similar to those in the CTV1 dosimetry (Fig. 1). A possible explanation for this is that the volumetric dose parameters in a larger target (CTV2) were less sensitive to the same couch shifts. If we used a 7-mm PTV margin, the CTV2 dosimetry would be even less affected by the simulated interobserver variability compared to the use of a 5-mm PTV margin. In addition, pelvic lymph nodes were irradiated for prophylactic purposes. Therefore, the TCPs of CTV2 were not included in this study.

Interestingly, the NTCPs of the rectum were deemed to be highly influenced by the simulated interobserver variability, while the NTCPs of the bladder were not. This result may be explained by the fact that the

![Fig. 5 An example of interobserver variability impact on dose distribution and dose volumetric histogram. The left and right dose distribution refer to the resulting dose distribution of prostate alignment and a 2-mm couch shift in the posterior direction, respectively. The solid dose volumetric histogram refers to prostate alignment, and the dashed dose volumetric histogram refers to a 2-mm couch shift in the posterior direction.](image-url)
average NTCPs of the bladder ranged from 0.75 to 1.12 (%) among the potential patient positions. In other words, the changes in the NTCPs of the bladder were negligibly small. Moreover, this is consistent with the fact that the bladder is less radiosensitive than the rectum [11]. The volumetric dose parameters and NTCPs of the rectum were highly influenced by the couch shift in the AP direction, while those of the bladder were sensitive to the couch shifts in both the AP and SI directions (Additional file 2). This inconsistency may be due to the bladder being located in the direction superior to the high-dose PTV (PTV1).

The TCPs of the target can be effectively ensured by prostate alignment despite the interobserver variability in CBCT-based soft-tissue matching. The NTCPs of the rectum were deemed to be highly influenced by interobserver variability, while the NTCPs of the bladder were not. This provides a theoretical explanation for the prostate-rectum interface soft-tissue matching procedure [24]. More specifically, emphasis should be placed on both the rectum and the prostate in CBCT-based soft-tissue matching. In addition, compared with fiducial-based target localization, volumetric CBCT-based soft-tissue matching is superior in utilizing anatomical information for the potential use of OAR sparing. For this reason, daily IGRT is superior to weekly IGRT. However, previous clinical trials [25–29] mainly focused on analyzing the IGRT-based PTV margin reduction for OARs sparing. Therefore, detailed investigations are needed to establish the clinical protocol for a specific IGRT technique [30].

Besides, Fiandra et al. [3] reported that the average interobserver variability between senior radiation oncologists and radiation therapists in LR, SI, and AP directions were 1.32 mm, 1.69 mm, and 2.05 mm, respectively. Similarly, the results in the study of Jereczek-Fossa et al. [6] were 1.9 mm, 0.9 mm, and −0.7 mm. Recently, Hirose et al. [5] took contour-based patient positioning as a reference, and found that the average interobserver variations among six experienced radiation therapists in LR, SI, and AP directions were 0.5, 0.9, and 0.9 mm, respectively. Therefore, in this study, maximum couch shifts of 2 mm relative to the resulting patient position of prostate alignment were used for interobserver variability simulation. Furthermore, we simulated a maximum couch shift of 5 mm (with 1 mm stepwise) in anterior and posterior directions for one treatment fraction, and found highly linearity between the NTCPs of the rectum and couch shifts in the anterior and posterior direction (Additional file 3).

The main drawback of this study is that the data from the prostate gland and the seminal vesicles were combined for analysis. As a result, the movements of the seminal vesicles independent of the prostate gland were not quantified. Therefore, in the process of CBCT-based soft-tissue matching, we ensured that the prostate gland and seminal vesicles were inside the prescription isodose line of the planned dose distribution. The results in this study showed that the CTV dosimetry and TCP were negligibly affected, although seminal vesicles move independently of the prostate. Besides, from the physical point of view, the variations of the patients without elective nodal irradiation are a subset of those of the patients with elective nodal irradiation. Thus, the conclusion obtained from the patients with elective nodal irradiation can be extrapolated to the patients without elective nodal irradiation.

Conclusions

In conclusion, we have proposed one method to simulate interobserver variability in CBCT-based soft-tissue matching. The TCP/NTCP analysis showed that the NTCPs of the rectum, rather than the TCPs of the target, were highly influenced by the interobserver variability in CBCT-based soft-tissue matching. More specifically, the NTCPs of the rectum were highly linearly correlated with the couch shifts in the anterior–posterior direction. These provide theoretical guidance in prostate IGRT clinical practices: (1) emphasis should be placed on both the rectum and the prostate in CBCT-based soft-tissue matching; (2) compared with fiducial-based target localization, volumetric CBCT-based soft-tissue matching is superior in utilizing anatomical information for the potential use of OAR sparing; (3) daily IGRT is superior to weekly IGRT.

Abbreviations

CBCT: Cone-beam CT; IGRT: Image-guided radiotherapy; OARs: Organ at risks; CTV: Clinical target volume; PTV: Planning target volume; TCP: Tumor control probability; NTCP: Normal tissue complication probability; ANOVA: One-way analysis of variance; AP: Anterior–posterior; SI: Superior–inferior.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13014-022-02034-1.

Additional file 1. The absolute and relative volume variations of the rectum and bladder.

Additional file 2. The resulting P values of paired t-test for the normal tissue complication probabilities (NTCPs) of the rectum (left) and bladder (right).

Additional file 3. Relationships between couch shifts in the anterior and posterior direction and the TCPs of the target and the NTCPs of the rectum for one treatment fraction.
Acknowledgements
Not applicable.

Authors’ contributions
XZ designed the study, collected data, analyzed data, and drafted the manuscript. XW, XL, LZ, SN, CL, XW, GD, and ZD helped to collect the data. RZ designed the study, revised and finally approved the manuscript. All authors read and confirmed the manuscript.

Funding
This work was supported by the Science and Technology Support Program of Sichuan province, China (No. 2021YFQ0065), the 1.3.5 project for disciplines of excellence–Clinical Research Incubation Project, West China Hospital, Sichuan University (No. 2021HSPH029), the National Natural Science Foundation of China (No. 11905150).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
This study was approved by the Ethics Committee of West China School of Medicine, Sichuan University (No. 20191128). All patients signed an informed consent form before radiotherapy.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 23 October 2021 Accepted: 15 March 2022 Published online: 01 April 2022

References
1. Mohler James L, Antonarakis Emmanuel S, Armstrong Andrew J, et al. Prostate cancer, Version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(5):479–505.
2. Ghadjar P, Fiorino C, Munck Af Rosenschöld P, Pinkawa M, Zilli T, van der Heide UA. ESTRO-ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer. Radiother Oncol. 2019;141:5–13.
3. Christian F, Alessia G, Fernando M, et al. Impact of the observers’ experience on daily prostate localization accuracy in ultrasound-guided IGRT with the Clarity platform. J Appl Clin Med Phys. 2014;15(4):168–73.
4. Deegan T, Owen R, Holt T, et al. Assessment of cone beam CT registration for prostate radiation therapy: Fiducial marker and soft tissue methods. J Med Imaging Radiat Oncol. 2015;59(1):91–8.
5. Hirose T-A, Amiruma H, Fukunaga J-I, Ohga S, Yoshitake T, Shioyama Y. Observer uncertainties of soft tissue-based patient positioning in IGRT. J Appl Clin Med Phys. 2020;20(2):73–81.
6. Jereczek-Fossa BA, Pobbiati C, Santoro L, et al. Prostate positioning using cone-beam computer tomography based on manual soft-tissue registration: Interobserver agreement between radiation oncologists and therapists. Strahlentherapie Onkol. 2014;190(1):81–7.
7. Morrow NV, Lawton CA, Qi XS, Li YA. Impact of computed tomography image quality on image-guided radiation therapy based on soft tissue registration. Int J Radiat Oncol Biol Phys. 2012;82(5):e733–8.
8. Moseley DJ, White EA, Wiltshire KL, et al. Comparison of localization performance with implanted fiducial markers and cone-beam computed tomography for on-line image-guided radiotherapy of the prostate. Int J Radiat Oncol Biol Phys. 2007;67(3):942–53.
9. Sachapazidis I, Mavroidis P, Zamboglou C, Klein CM, Grosu A-L, Baltas D. Prostate cancer tumour control probability modelling for external beam radiotherapy based on multi-parametric MRI-GTV definition. Radiat Oncol. 2020;15(1):242.
10. Burman C, Kutcher GJ, Erami B, Goitein M. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys. 1991;21(1):123–35.
11. Rana S, Cheng CS. Radiobiological impact of planning techniques for prostate cancer in terms of tumor control probability and normal tissue complication probability. Ann Med Health Sci Res. 2014;4(2):167–72.
12. Okunieff P, Morgan D, Niemierko A, et al. Radiation dose-response of human tumors. Int J Radiat Oncol Biol Phys. 1995;32(4):1227.
13. Seabold S, Perktold J. Statsmodels: Econometric and statistical modeling with python. In: Python in science conference. 2010.
14. Napieralska A, Majewski W, Kulik R, Głowacki G, Miszczuk L. A comparison of treatment outcome between fiducial-based and bone-based image guided radiotherapy in prostate cancer patients. Radiother Oncol. 2018;123(1):133.
15. Kotecha R, Djemil T, Tendulkar RD, et al. Dose-escalated stereotactic body radiation therapy for patients with intermediate- and high-risk prostate cancer: initial dosimetry analysis and patient outcomes. Int J Radiat Oncol Biol Phys. 2016;95(3):960–4.
16. Li W, Lu L, Stephens KL, et al. Volumetric-based image guidance is superior to marker-based alignments for stereotactic body radiotherapy of prostate cancer. J Appl Phys Med Phys. 2018;19(2):196–203.
17. Maund IF, Benson RJ, Fair foul J, Cook J, Huddart R, Poynter A. Image-guided radiotherapy of the prostate using daily CBCT: the feasibility and likely benefit of implementing a margin reduction. Br J Radiol. 2014;87(1044):20140459.
18. Gill SK, Reddy K, Campbell N, Chen C, Pearson D. Determination of optimal PTV margin for patients receiving CBCT-guided prostate IMRT: comparative analysis based on CBCT dose calculation with four different margins. J Appl Clin Med Phys. 2015;16(6):252–62.
19. Zhang Y, Zhang X, Li J, et al. Analysis of the influence of peripheral anatomical changes for CBCT-guided prostate cancer radiotherapy. Technol Cancer Res Treat. 2021;20:15330338211016370.
20. Huttenrauch P, Witt M, Wolff D, et al. Target volume coverage and dose to organs at risk in prostate cancer patients. Dose calculation on daily cone-beam CT data sets. Strahlenther Onkol. 2014;190(3):310–6.
21. Gawish A, Chughtai AA, Ebele MJ. Dosimetric and volumetric effects on clinical target volumes and risk organs during the Strahlentherapie nach Prostatektomie. Strahlentherapie Onkol. 2019;195(5):383–92.
22. Mayyas E, Kim J, Kumar S, et al. A novel approach for evaluation of prostate deformation and associated dosimetric implications in IGRT of the prostate. Med Phys. 2014;41(9):91709.
23. Shelton J, Rossi PJ, Chen H, Liu Y, Master VA, Jani AB. Observations on prostate intrafraction motion and the effect of reduced treatment time using volumetric modulated arc therapy. Pract Radiat Oncol. 2011;1(4):243–50.
24. Tak Chean KC, Nguyen J. A retrospective analysis investigating feasibility of the prostate-rectum interface soft-tissue image matching procedure for prostate cancer patients without gold seeds at the Durham regional cancer centre. J Med Imaging Radiat Sci. 2015;46(1):S4–5.
25. Valeriani M, Bracci S, Osti MF, et al. Intermediate-risk prostate cancer patients treated with androgen deprivation therapy and a hyperfractionated radiation regimen with or without image-guided radiotherapy. Radiat Oncol. 2013;8:137.
26. Sveistrup J, af Rosenschöld PM, Deasy JO, et al. Improvement in toxicity of prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. Radiat Oncol. 2014;9:44.
27. Singh J, Greer PB, White MA, et al. Treatment-related morbidity in prostate cancer: a comparison of 3-dimensional conformal radiation therapy with and without image guidance using implanted fiducial markers. Int J Radiat Oncol Biol Phys. 2013;85(4):1018–23.
28. Zapatero A, Roch M, Büchser D, et al. Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer. Clin Transl Oncol. 2017;19(9):1161–7.
29. Chung HT, Xia P, Chan LW, Park-Somers E, Roach M. Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT. Int J Radiat Oncol Biol Phys. 2009;73(1):53–60.
30. Bissonnette J-P, Balter PA, Dong L, et al. Quality assurance for image-guided radiation therapy utilizing CT-based technologies: A report of the AAPM TG-179. Med Phys. 2012;39(4):1946–63.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.